Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Phase 2RecruitingDevelopment Stage
Lymphoma, Non-Hodgkin
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Mar 14, 2016 → Dec 31, 2028
About Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD) is a phase 2 stage product being developed by Eli Lilly for Lymphoma, Non-Hodgkin. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02693535. Target conditions include Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Non-Hodgkin were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02693535 | Phase 2 | Recruiting |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin